309 related articles for article (PubMed ID: 18001259)
1. The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes.
Mikhailidis DP; Press M
Expert Opin Pharmacother; 2007 Dec; 8(17):3009-20. PubMed ID: 18001259
[TBL] [Abstract][Full Text] [Related]
2. The importance of treating cardiometabolic risk factors in patients with type 2 diabetes.
Barnett AH
Diab Vasc Dis Res; 2008 Mar; 5(1):9-14. PubMed ID: 18398806
[TBL] [Abstract][Full Text] [Related]
3. Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction.
Basile J; Houston M; Ferrario CM
J Cardiometab Syndr; 2006; 1(5):358-61. PubMed ID: 17679795
[No Abstract] [Full Text] [Related]
4. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
Després JP
Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S53-61. PubMed ID: 14502101
[TBL] [Abstract][Full Text] [Related]
5. Overweight and obesity: the pathogenesis of cardiometabolic risk.
Bray GA; Clearfield MB; Fintel DJ; Nelinson DS
Clin Cornerstone; 2009; 9(4):30-40; discussion 41-2. PubMed ID: 19789062
[TBL] [Abstract][Full Text] [Related]
6. Polycystic ovary syndrome, adipose tissue and metabolic syndrome.
Delitala AP; Capobianco G; Delitala G; Cherchi PL; Dessole S
Arch Gynecol Obstet; 2017 Sep; 296(3):405-419. PubMed ID: 28643028
[TBL] [Abstract][Full Text] [Related]
7. Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk.
Calabro P; Yeh ET
Curr Hypertens Rep; 2008 Feb; 10(1):32-8. PubMed ID: 18367024
[TBL] [Abstract][Full Text] [Related]
8. [The adiponectin to leptin ratio, a still unrecognized biomarker of insulin resistance and cardiometabolic risk].
Vatier C; Antuna-Puente B; Fellahi S; Vigouroux C; Capeau J; Bastard JP;
Ann Biol Clin (Paris); 2020 Jun; 78(3):265-268. PubMed ID: 32420886
[TBL] [Abstract][Full Text] [Related]
9. The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in type 2 diabetes with particular focus on the emerging role of the thiazolidinediones.
Greenberg AS
J Diabetes Complications; 2003; 17(4):218-28. PubMed ID: 12810246
[TBL] [Abstract][Full Text] [Related]
10. [Fat mass expansion, fatty acids and adipokines: metabolic markers and risk factors for cardiovascular pathologies].
Lafontan M
Ann Pharm Fr; 2013 Jan; 71(1):13-26. PubMed ID: 23348852
[TBL] [Abstract][Full Text] [Related]
11. Interrelationships between inflammation, C-reactive protein, and insulin resistance.
Ndumele CE; Pradhan AD; Ridker PM
J Cardiometab Syndr; 2006; 1(3):190-6. PubMed ID: 17679826
[TBL] [Abstract][Full Text] [Related]
12. Organokines in disease.
Chung HS; Choi KM
Adv Clin Chem; 2020; 94():261-321. PubMed ID: 31952573
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk of adipokines: a review.
Dutheil F; Gordon BA; Naughton G; Crendal E; Courteix D; Chaplais E; Thivel D; Lac G; Benson AC
J Int Med Res; 2018 Jun; 46(6):2082-2095. PubMed ID: 28974138
[TBL] [Abstract][Full Text] [Related]
14. Adipokines at the crossroad between obesity and cardiovascular disease.
Molica F; Morel S; Kwak BR; Rohner-Jeanrenaud F; Steffens S
Thromb Haemost; 2015 Mar; 113(3):553-66. PubMed ID: 25338625
[TBL] [Abstract][Full Text] [Related]
15. Adipose-Vascular Coupling and Potential Therapeutics.
Gollasch M
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():417-436. PubMed ID: 27732801
[TBL] [Abstract][Full Text] [Related]
16. Clusterin and Its Role in Insulin Resistance and the Cardiometabolic Syndrome.
Wittwer J; Bradley D
Front Immunol; 2021; 12():612496. PubMed ID: 33717095
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.
Esser N; Paquot N; Scheen AJ
Expert Opin Investig Drugs; 2015 Mar; 24(3):283-307. PubMed ID: 25345753
[TBL] [Abstract][Full Text] [Related]
18. Abdominal adiposity and cardiometabolic risk: do we have all the answers?
Haffner SM
Am J Med; 2007 Sep; 120(9 Suppl 1):S10-6; discussion S16-7. PubMed ID: 17720354
[TBL] [Abstract][Full Text] [Related]
19. Adipokines--targeting a root cause of cardiometabolic risk.
Bakhai A
QJM; 2008 Oct; 101(10):767-76. PubMed ID: 18550581
[TBL] [Abstract][Full Text] [Related]
20. Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes.
Gardner M; Palmer J; Manrique C; Lastra G; Gardner DW; Sowers JR
J Cardiometab Syndr; 2009; 4(2):96-101. PubMed ID: 19614796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
